Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Curvietto M"" wg kryterium: Autor


Tytuł :
EP-1392: The abscopal effect:efficacy of radiotherapy in patients on progression after ipilimumab 3 mg/kg
Autorzy :
Grimaldi, A.M.
Ascierto, P.A.
Simeone, E.
Giannarelli, D.
Falivene, S.
Borzillo, V.
Giugliano, F.
Sandomenico, F.
Petrillo, A.
Curvietto, M.
Esposito, A.
Paone, M.
Palla, M.
Palmieri, G.
Caraco, C.
Ciliberto, G.
Mozzillo, N.
Muto, P.
Pokaż więcej
Źródło :
In ESTRO 35, 29 April - 3 May 2016, Turin, Italy, Radiotherapy and Oncology April 2016 119 Supplement 1:S649-S650
Czasopismo naukowe
Tytuł :
3346 BeyPro1: a Phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the V600BRAF mutation and pretreated with Vemurafenib, with the association of Vemurafenib plus Fotemustine
Autorzy :
Queirolo, P.
Spagnolo, F.
Picasso, V.
Simeone, E.
Grimaldi, A.M.
Curvietto, M.
Giorello, L.
Fontana, V.
Merlo, D.F.
Ascierto, P.A.
Bruzzi, P.
Pokaż więcej
Źródło :
In Abstracts from the European Cancer Congress 2015, European Journal of Cancer September 2015 51 Supplement 3:S683-S683
Czasopismo naukowe
Tytuł :
PP 65 Are GSK2118436 and GSK1120212 effective in melanoma cell lines harboring V600BRAF mutations different from the common V600EBRAF variant?
Autorzy :
Ascierto, P.A.
Gentilcore, G.
Madonna, G.
Assunta, E.
Pirozzi, G.
De Maio, E.
Curvietto, M.
Palmieri, G.
Mozzillo, N.
Legos, J.
Pokaż więcej
Źródło :
In Abstracts of the EORTC - NCI - ASCO Annual Meeting on 'Molecular Markers in Cancer', European Journal of Cancer 2011 47 Supplement 4:S11-S11
Czasopismo naukowe
Tytuł :
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.
Autorzy :
Ottaviano M; Oncology Unit, Ospedale del Mare, Napoli, Campania, Italy.; Department of Clinical Medicine and Surgery, Università degli Studi di Napoli Federico II and CRCTR Coordinating Rare Tumors Reference Center of Campania Region, AOU Federico II, Napoli, Italy.
Curvietto M; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Rescigno P; Clinical Studies, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
Tortora M; CRCTR Coordinating Rare Tumors Reference Center of Campania Region, AOU Federico II, Napoli, Campania, Italy.
Palmieri G; CRCTR Coordinating Rare Tumors Reference Center of Campania Region, AOU Federico II, Napoli, Campania, Italy.
Giannarelli D; Biostatistics Unit, IRCCS Regina Elena National Cancer Institute, Roma, Lazio, Italy.
Aieta M; Medical Oncology Unit, Department of Onco-Hematology, IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Basilicata, Italy.
Assalone P; Oncology Unit, Ospedale Ferdinando Veneziale, Isernia, Molise, Italy.
Attademo L; Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Avallone A; Abdominal Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Bloise F; Medical Oncology Unit, University of Pisa, Pisa, Toscana, Italy.
Bosso D; Oncology Unit, Ospedale del Mare, Napoli, Italy.
Borzillo V; Department of Radioterapia, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Buono G; Oncology Unit, San Rocco Hospital, Sessa Aurunca, Campania, Italy.
Calderoni G; Oncology Unit, Ospedale Della Murgia, Bari, Puglia, Italy.
Caputo F; U.O.C. Oncologia, Azienda Ospedaliera dei Colli, Monaldi Hospital, Napoli, Campania, Italy.
Cartenì G; Department of Medical Oncology, AORN 'A. Cardarelli', Napoli, Campania, Italy.
Cavallero D; Medical Oncology Unit, University of Pisa, Pisa, Toscana, Italy.
Cavo A; Oncology Unit, Villa Scassi Hospital, Genova, Italy.
Ciardiello F; Oncology, Department of Precision Medicine, Università della Campania 'L. Vanvitelli', Napoli, Campania, Italy.
Conca R; Medical Oncology Unit, Department of Onco-Hematology, IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Basilicata, Italy.
Conteduca V; Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Emilia-Romagna, Italy.
De Falco S; Oncology Unit, Sant'Ottone Frangipane Hospital, Avellino, Campania, Italy.
De Felice M; Oncology, Department of Precision Medicine, Università della Campania 'L. Vanvitelli', Napoli, Campania, Italy.; Oncology Unit, Sant'Anna e San Sebastiano, Caserta, Campania, Italy.
De Laurentiis M; Breast Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
De Placido P; Department of Clinical Medicine and Surgery, Oncology Unit, Università degli Studi di Napoli Federico II, Napoli, Campania, Italy.
De Placido S; CRCTR Coordinating Rare Tumors Reference Center of Campania Region, AOU Federico II, Napoli, Campania, Italy.; Department of Clinical Medicine and Surgery, Oncology Unit, Università degli Studi di Napoli Federico II, Napoli, Campania, Italy.
De Santo I; Oncology Unit, Gemelli Molise s.p.a, Campobasso, Molise, Italy.
De Stefano A; Abdominal Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Della Corte CM; Oncology, Department of Precision Medicine, Università della Campania 'L. Vanvitelli', Napoli, Campania, Italy.
Di Franco R; Department of Radioterapia, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Di Lauro V; Breast Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.; Department of Clinical Medicine and Surgery, Oncology Unit, Università degli Studi di Napoli Federico II, Napoli, Campania, Italy.
Fabbrocini A; Oncology Unit, Ospedale del Mare, Napoli, Italy.
Federico P; Oncology Unit, Ospedale del Mare, Napoli, Italy.
Festino L; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Giordano P; Oncology Unit, Ospedale del Mare, Napoli, Italy.
Giuliano M; CRCTR Coordinating Rare Tumors Reference Center of Campania Region, AOU Federico II, Napoli, Campania, Italy.; Department of Clinical Medicine and Surgery, Oncology Unit, Università degli Studi di Napoli Federico II, Napoli, Campania, Italy.
Gridelli C; Division of Medical Oncology, 'San Giuseppe Moscati' Hospital, Avellino, Campania, Italy.
Grimaldi AM; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Lia M; Oncology Unit, SS Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Piemonte, Italy.
Marretta AL; Department of Clinical Medicine and Surgery, Oncology Unit, Università degli Studi di Napoli Federico II, Napoli, Campania, Italy.
Massa V; Medical Oncology Unit, University of Pisa, Pisa, Toscana, Italy.
Mennitto A; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy.
Merler S; Department of Oncology, University of Verona, Verona, Veneto, Italy.
Merz V; Department of Medical Oncology, Santa Chiara Hospital, Trento, Trentino Alto Adige, Italy.
Messina C; Department of Medical Oncology, Santa Chiara Hospital, Trento, Trentino Alto Adige, Italy.
Messina M; UOC Oncologia Medica, Ospedali Riuniti Villa Sofia Cervello, Palermo, Sicilia, Italy.
Milano M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy.
Minisini AM; Department of Oncology, Azienda Sanitaria Universitaria Integrata del Friuli Centrale, Udine, Friuli Venezia Giulia, Italy.
Montesarchio V; U.O.C. Oncologia, Azienda Ospedaliera dei Colli, Monaldi Hospital, Napoli, Campania, Italy.
Morabito A; Thoracic Medical Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Morgillo F; Oncology, Department of Precision Medicine, Università della Campania 'L. Vanvitelli', Napoli, Campania, Italy.
Mucci B; Department of Clinical Medicine and Surgery, Oncology Unit, Università degli Studi di Napoli Federico II, Napoli, Campania, Italy.
Nappi L; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada and British Columbia Cancer Agency-Vancouver Center-Department of Medicine, Division of Medical Oncology, University of British Columbia, Vancouver, British Columbia, Canada.
Napolitano F; Department of Clinical Medicine and Surgery, Oncology Unit, Università degli Studi di Napoli Federico II, Napoli, Campania, Italy.
Paciolla I; Oncology Unit, Ospedale Sacro Cuore di Gesù Fatebenefratelli, Benevento, Campania, Italy.
Pagliuca M; Department of Clinical Medicine and Surgery, Oncology Unit, Università degli Studi di Napoli Federico II, Napoli, Campania, Italy.
Palmieri G; Institute of Research on Genetics and Biomedicine (IRGB), National Research Council (CNR), Sassari, Sardegna, Italy.
Parola S; Department of Clinical Medicine and Surgery, Oncology Unit, Università degli Studi di Napoli Federico II, Napoli, Campania, Italy.
Pepe S; Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', Oncology Unit, University of Salerno, Baronissi, Campania, Italy.
Petrillo A; Oncology Unit, Ospedale del Mare, Napoli, Italy.; Oncology, Department of Precision Medicine, Università della Campania 'L. Vanvitelli', Napoli, Campania, Italy.
Piantedosi F; U.O.C. Pneumologia Oncologica, Azienda Ospedaliera dei Colli, Monaldi Hospital, Naples, Campania, Italy.
Piccin L; Veneto Institute of Oncology IOV-IRCCS, Padova, Veneto, Italy.
Picozzi F; Department of Clinical Medicine and Surgery, Oncology Unit, Università degli Studi di Napoli Federico II, Napoli, Campania, Italy.
Pietroluongo E; Department of Clinical Medicine and Surgery, Oncology Unit, Università degli Studi di Napoli Federico II, Napoli, Campania, Italy.
Pignata S; Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Prati V; Medical Oncology Unit, ASL CN2, Alba, Piemonte, Italy.
Riccio V; Department of Clinical Medicine and Surgery, Oncology Unit, Università degli Studi di Napoli Federico II, Napoli, Campania, Italy.
Rosanova M; Oncology Unit, Ospedale del Mare, Napoli, Italy.
Rossi A; Department of Oncology, University of Verona, Verona, Veneto, Italy.
Russo A; Medical Oncology Unit, Fondazione IRCCS Giovanni Paolo II, Bari, Puglia, Italy.
Salati M; Medical Oncology Unit, University Hospital Modena, Modena, Emilia Romagna, Italy.
Santabarbara G; Division of Medical Oncology, 'San Giuseppe Moscati' Hospital, Avellino, Campania, Italy.
Sbrana A; Medical Oncology Unit, University of Pisa, Pisa, Toscana, Italy.
Simeone E; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Silvestri A; Oncology Unit, Ospedale del Mare, Napoli, Italy.
Spada M; Oncology Unit, Fondazione Istituto San Raffaele G Giglio di Cefalu, Cefalu, Sicilia, Italy.
Tarantino P; Division of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milano, Lombardia, Italy.
Taveggia P; Oncology Unit, Villa Scassi Hospital, Genova, Italy.
Tomei F; Oncology Unit, Ospedale Ferdinando Veneziale, Isernia, Molise, Italy.
Vincenzo T; Department of Clinical Medicine and Surgery, Oncology Unit, Università degli Studi di Napoli Federico II, Napoli, Campania, Italy.; Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', Oncology Unit, University of Salerno, Baronissi, Campania, Italy.
Trapani D; Division of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milano, Lombardia, Italy.
Trojanello C; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Vanella V; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Vari S; Medical Oncology 1 Unit, IRCCS Regina Elena National Cancer Institute, Rome, Lazio, Italy.
Ventriglia J; Oncology Division, ASL San Felice a Cancello, Caserta, Campania, Italy.
Vitale MG; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.; Department of Oncology, Azienda Sanitaria Universitaria Integrata del Friuli Centrale, Udine, Friuli Venezia Giulia, Italy.
Vitiello F; U.O.C. Pneumologia Oncologica, Azienda Ospedaliera dei Colli, Monaldi Hospital, Naples, Campania, Italy.
Vivaldi C; Medical Oncology Unit, University of Pisa, Pisa, Toscana, Italy.
von Arx C; Department of Surgery and Cancer, Imperial College, London, UK.
Zacchi F; Oncology Unit, Università degli Studi di Verona, sede Borgo Roma, Verona, Veneto, Italy.
Zampiva I; Oncology Unit, Università degli Studi di Verona, sede Borgo Roma, Verona, Veneto, Italy.
Zivi A; Department of Surgery and Cancer, Imperial College, London, UK.; Medical Oncology Department, AOUI di Verona, Verona, Veneto, Italy.
Daniele B; Oncology Unit, Ospedale del Mare, Napoli, Italy.
Ascierto PA; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy .
Pokaż więcej
Corporate Authors :
SCITO (Società Campana di ImmunoTerapia Oncologica)
Źródło :
Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Oct; Vol. 8 (2).
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Immunological/*administration & dosage
Betacoronavirus/*immunology
Coronavirus Infections/*epidemiology
Medical Oncology/*statistics & numerical data
Neoplasms/*drug therapy
Pneumonia, Viral/*epidemiology
Adult ; Antineoplastic Agents, Immunological/adverse effects ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/immunology ; Betacoronavirus/pathogenicity ; CTLA-4 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/immunology ; Coronavirus Infections/immunology ; Coronavirus Infections/prevention & control ; Coronavirus Infections/transmission ; Drug Prescriptions/statistics & numerical data ; Female ; Geography ; Humans ; Infection Control/standards ; Italy/epidemiology ; Male ; Medical Oncology/standards ; Neoplasms/immunology ; Oncologists/statistics & numerical data ; Pandemics/prevention & control ; Pneumonia, Viral/immunology ; Pneumonia, Viral/prevention & control ; Pneumonia, Viral/transmission ; Practice Patterns, Physicians'/standards ; Practice Patterns, Physicians'/statistics & numerical data ; Prevalence ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology ; Surveys and Questionnaires/statistics & numerical data ; Time-to-Treatment
SCR Disease Name :
COVID-19
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies